TH_logo_couleur.png
Triple Hair Group reçoit l'approbation de l'EMA pour commencer les essais cliniques de phase III sur son médicament sur ordonnance Thérapie-07 en Europe
June 19, 2024 07:30 ET | Triple Hair Inc.
MONTRÉAL, 19 juin 2024 (GLOBE NEWSWIRE) -- Triple Hair Group Inc. (« Triple Hair » ou la « Société »), une société spécialisée dans le développement de traitements novateurs contre l'alopécie...
TH_logo_couleur.png
Triple Hair Group Receives EMA Approval to Start Phase III Clinical Trials on its Therapy-07 Prescription Drug in Europe
June 19, 2024 07:30 ET | Triple Hair Inc.
MONTRÉAL, June 19, 2024 (GLOBE NEWSWIRE) -- Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for androgenic alopecia,...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 24, 2024 07:05 ET | Travere Therapeutics, Inc.
Travere and CSL Vifor announce EC approval of FILSPARI (sparsentan) for treatment of IgAN, 1st non-immunosuppressive treatment for IgAN approved in Europe
1 CHPI 1080 copy.png
Waiting for new medicines in Canada, Europe, and the United States: Study finds Americans get better and faster access to innovative drugs
April 11, 2024 10:30 ET | Canadian Health Policy Institute Inc.
Americans get better and faster access to innovative medicines compared to Europeans and Canadians.
1 CHPI 1080 copy.png
Access to new medicines in Canada, Europe, and the United States: Study finds less availability and longer waits for Canadian patients
April 11, 2024 10:00 ET | Canadian Health Policy Institute Inc.
A recent study published by the Canadian Health Policy Institute examined the availability and wait times for access to new drugs.
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
February 23, 2024 07:05 ET | Travere Therapeutics, Inc.
Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe ...
NurExone logo2.png
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
February 02, 2024 16:05 ET | NurExone Biologic Inc
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product
Logo.jpg
Ecological Momentary Assessment Market To Reach USD 59.9 Million By 2032, Says DataHorizzon Research
January 18, 2024 07:10 ET | DataHorizzon Research
Fort Collins, Colorado, Jan. 18, 2024 (GLOBE NEWSWIRE) -- The Ecological Momentary Assessment Market was valued at USD 12.1 Million in 2022 and is anticipated to grow CAGR at 17.4% to reach USD 59.9...
OpsMx Logo.png
OpsMx Named to First Annual EMA Allstars 2024 List
January 10, 2024 16:21 ET | OpsMx
SUNNYVALE, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- OpsMx, the leader in secure software delivery, today announced it is featured in the inaugural 2024 EMA Allstars list in the “DevSecOps Platform...
Logo.jpg
Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results
November 13, 2023 09:00 ET | Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...